Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@grandslam... We don't know either way. That's the problem. They don't talk to the shareholders anymore outside of the SEC filings (which are great to have, but don't explain what's really happening, or perhaps not happening). They've obviously had a lot of difficulty pricing their IPOs, since this is the third or fourth attempt at it, in addition to the one brief attempt to do a listing without the IPO. But we have no idea why. The IPOScoop site, which tends to have decent data, does not list it as "withdrawn" yet, so perhaps they are still trying. I do wonder if there are IP concerns in the investment world, as I have no idea if they have obtained actual patents on the critical technologies (those being, in my view, AlloRx itself, and parts of their manufacturing platform). Since they don't communicate with us, there is no way to know if that is an issue, and, if not, what the problem is.
LOL. Absurd. So the $3M goes up in smoke, if there ever was $3M that is.
Well, it's been almost three weeks since the latest S-1, and... nothing. I have to assume that the latest attempt at an IPO has failed just like the others. But, given this company's outstanding recent history of shareholder relations, who knows.... certainly not the shareholders.
Seems a big thing here would be the experimental treatments available under our Right to Try Act, allowing patients with life-threatening illnesses, who are unable to participate in a clinical trial, to access drugs - including biologics - that have not yet been approved by the FDA.
Yeah, there weren't many COVID data points, though they actually did release the numbers on those cases in their various filings in the past year. Unfortunately, that all coincided with the Giostar thing, which I found unfortunate (there was a legit research physician involved, but the overall image of that company reeked of stem cell scam to me -- I'm glad it faded away). I was referring more to the offshore treatments they've been doing for years, servicing the medical tourism businesses in the Caymans and Bahamas. Interestingly enough, one of their patients was Kirk Cousins, who led the Falcons to a last-second win over the Eagles on Monday Night Football this week. He tore his Achilles last season, and had AlloRx treatments earlier this year to assist with his recovery. So if the Falcons end up in the Super Bowl, VB can claim all the credit ...JK. Seriously though, the safety data that I imagine influenced the FDA's decision to approve their clinical trials comes mostly from all those medical tourism cases. Those count for the purposes of getting a domestic trial approved, but not for much else.
I do recall the results that were published, shortly before the delisting, about successfully treating COVID symptoms. It might have been just one person lol, but seems they were on a ventilator (i.e., on death's doorstep) and, after getting the treatment, recovered completely.
Re the early trading dynamics if/when the IPO succeeds, I think we've discussed that a number of times as the months have turned into years. I'd expect a short-term drop, as people anxious to exit for literally years try to liquidate immediately. Whether there is some value-based demand after that is difficult to tell -- but, with a float this small, it only takes a few bullish quasi-insiders to absorb enough shares to create a tailwind. After that, it's entirely a function of how the clinical trials go. And I expect the initial results to be good, since it's basically about safety at that stage, and they have plenty of offshore data to expect little or no problem with that. Of course, if they see unexpected early efficacy on top of establishing safety, that's when things get really interesting. If I remember correctly, Mesoblast had a couple billion dollar valuation at one point (I could be wrong about that, but I know it topped a billion). Should that happen with VTRO, investors from the penny stock days would see something like a 5,000-6,000% ROI, not accounting for further dilution beyond all the outstanding notes and warrants, some of which is inevitable. I don't expect anything that good to happen, but it's possible -- it doesn't take too too much good news in the biotech world to create a billion dollar valuation.
Ok! Good to see. If it does happen, will be interesting to see where the price settles. After being frozen out for 3+ years, will many people head for the exits, just to realize some return on their investment?
FWIW, the SEC issued the "Notice of Effectiveness" for the S-1 / IPO. That means the offering is blessed as legit, and the company can go ahead and put the securities on the market. That sounds to me like the underwriters have secured the funding, and this will likely be happening soon (although I don't think the one thing is technically connected to the other). We shall see. But I wouldn't be surprised if the thing finally happens relatively soon.
Insiders as well, if they are the ones doing the funding..... they're not going to throw good money after bad, either. Also, I'm thinking (perhaps delusionally) that trial(s) might already be ongoing, and they're waiting on the results before doing PRs.
Yeah, that's the mystery. Who is keeping things afloat and why? And if it's a real outside investor or investor group (vs. continuous insider injection of personal capital), what do they see that, apparently, nobody else sees? They clearly had some plan for what has happened financially, else they would not have restructured with new hires and an unsustainable burn rate a couple years ago. As I've been saying over and over, this is why I am so disappointed in the CEOs who have succeeded Dr. Musick. Zamora was clearly just manipulating the situation (at least as I see it as an outsider, extrapolating from info they have put in filings) -- so, in retrospect, his near total silence is explainable. But I expected more of Furman. To be fair, he immediately put the company on a fast track to renewed legitimacy with the SEC (and, presumably also helped out with the FDA, although I think that was Mosessian's primary gig). And to be more fair, their SEC filings have been comprehensive. But what we haven't seen at all is any kind of personal media or communication that lays out basic strategy. That's part of a CEO's job, along with manufacturing a public image. Back in the day, Dr. Musick would put together a complete summary every quarter or at least a couple times a year, which I appreciated. But, like Zamora, Furman has done none of that. Actually, he has done less, since Zamora actually did do a couple brief interviews early on before going silent. Again, I don't want to minimize the effort that went into reorganizing and getting to the precipice of being a legit biotech startup. But a few basic questions remain unanswered, and I think it's time to let the legacy shareholders know what is going on and when these clinical trials will begin.
I see, thanks for breaking it down like that. I'd think that something must be brewing behind the scenes, for them to continue to get funding to (presumably) keep the lights on and (even more presumably) carry on with trials, R&D, etc. I think the latest monetary injection was $3M, last year. There must be some degree of confidence that that investment will be recouped, and then some. I know, tilting at windmills, but that's all we have right now.
The S-1 says that 4.5 million total shares exist now. I imagine that only about a million of those are truly held publicly (not by insiders). So that would be the approximate float now, if it were trading. The IPO will add roughly a million shares to that, so that would be two million. And then they imply that roughly 1.8 million shares will be created when all those notes and warrants that have been funding the company for the past few years are somehow (?) converted to shares. So the total float, assuming the IPO happens and all the other financial instruments convert, would probably be somewhere in the neighborhood of 4 million shares, maybe slightly less. It's a very small number for a public company. And it's the one faint hope for legacy investors, if some sort of tailwind should ever develop around the core business. With a float that small, any kind of broad-market demand for the shares will create serious upward pressure on the share price. On the bright side, they have at least done everything technically necessary to return to trading, and I certainly give them credit for that. Very few companies get delisted like they did and survive, let alone survive with their original shareholders mostly intact. It is very unusual. But until they execute an IPO or otherwise list the shares, it doesn't matter.
Tom, do we know what a ballpark new float might be? Hypothetically of course, given the long odds of any of this actually coming to fruition. In another era, many moons ago, I believe it was in the millions.
They amended the S-1 again. No time to read. There is a heavy-handed warning about spreading disinformation, and, at first glance, the whole note/warrant conversion thing seems off the table now. Which would make sense, as it could only scare away IPO investors. My guess is the two things are related, but who knows. No time to read it or worry about it anymore. Again, if the IPO actually happens, and the shares hold the $5-$6 IPO price, most speculators from the penny stock days will be somewhere between "whole" and "modestly ahead", depending on your average cost. From there it will be a weird battle between the very small float and the very small public awareness of the company -- no way to tell what wins. But, of course, none of it means anything unless the IPO actually executes. Which has been problematic so far. We'll see.
Tom, it certainly is puzzling, why they would continue to prepare for an IPO, as well as (presumably) carry on with the day-to-day, but without the marketing that is vital if an IPO is to succeed. Yet they must feel that this undertaking can ultimately pay off, otherwise why the continued activity. Perhaps they are waiting on promising trial results, and only then would they proceed in earnest? Us shareholders, as always, are left in the dark. Nothing new there!
For the masochists among us, they updated their IPO filing with the SEC. I have neither the time nor interest to read it in detail. It's all obviously ongoing back and forth between balancing new IPO shares vs. note/warrant holders demanding liquidity, finding an investment bank that can make it all work (good luck...), choosing an exchange, etc., etc. This one does specify that resale shares can't be sold until the IPO succeeds. Which makes sense, since the company probably can't survive without the IPO funds.
In the end, there are buyers for the shares or there aren't. And until they start selling themselves through media and a professional communication strategy (I mean, for the love of god, please update your website pipeline to not reference 2023...), I don't know how they can expect anyone to be interested. Man, I'd sure love to be paid a CEO's salary and not have to answer a question from a shareholder, ever. Nice work if you can get it, Chris. I don't know what dream world these people are living in, but hopefully they'll surprise us all and snap out of it soon.
Thanks for your take Tom, good to see that the fish on the dock is at still wiggling. As you say, it all comes down to the product, their last gasp would appear to be these trials that the new funding would allow to proceed. Best of luck to Dr. Z selling a million shares into a low-volume market. The hope, of course, is that the volume would increase considerably on the heels of any good news.
Re prior post, I decided to skim it quickly. It strikes me as a final shot at satisfying the company's pressing needs. (1) They need some money to start the clinical trials (without which, it’s game over and lights out), and, (2) based on this and prior filings, they apparently have a group of investors and former insiders who are pressing hard for a liquidity event. After the last IPO attempt failed, they were previously going to satisfy the latter by listing the shares and letting the market set a price. Apparently that plan failed, like everything else.they've tried. So now they're doing a two-pronged attack, where they do a bare minimum IPO to raise modest funding, and they let this privileged group of investors sell their stock separately (after some accounting gyrations to create the stock). The result, if it all works out, is a stock price of 5 or 6 bucks a share on the NYSE American. The elite group of prior investors presumably doesn't sue them (I imagine that’s in writing somewhere), and they raise 4 million or so to do the clinical trials.
The problem with all of these plans is that nobody has ever heard of this company, in large part because: they do no PR; the various CEOs have done no media or public appearances; and there is no buzz, and no awareness of what they even do. For any IPO or fundraising of any kind to work, there has to be awareness of what you do. This company has done nothing to create that awareness. They seem to expect that people will suddenly buy their shares because... well, I have no idea why they would expect that. My sense is that this plan will fail like all the others, due to lack of demand for the shares. But let's hope I'm wrong. This is the bare minimum offer they can execute that keeps most pink sheet investors whole while generating anything close to the cash they need to do the clinical trials. If this fails, I have to assume that it's game over.
Even if things go right, I do not expect any significant appreciation of the share price for a while, until (1) one or both clinical trials have encouraging Phase 1/2 results, and (2) the expected sell-off from the privileged investors is absorbed by the market. Good luck with the latter – I expect the SP to plunge initially, with a possible quick exile to the OTC markets. More specifically, it doesn’t say this specifically, but I suspect that Dr. Z will suddenly have a couple million fungible shares. And if you don’t think that dude will be cashing out ASAP, I have a bridge to sell you. If he can sell a couple million shares for a buck each, I imagine he would do that. But who knows -- this is speculation.
The only hope for longer-term, legacy investors (like me) is that the IPO actually succeeds and the clinical trials go exceptionally well. Given the very, very small float, any tailwind like this could, and probably would, send the share price to $20 or more based on pure speculation. My advice is to hope the IPO happens, prepare to ride out the inevitable sell-off from former insiders and their girlfriends and nieces, and hope that at least one of the two trials goes well. We will all make money if that happens, possibly a lot of money. But a lot has to go right. Honestly, I think the science end of it is a decent bet, as I think their underlying product proposition is solid and compelling. Whether they can convince the investment community to supply the capital to prove it is a much more tenuous proposition, particularly given their abysmal communication strategy (or total lack thereof).
https://www.sec.gov/edgar/browse/?CIK=793171 Honestly, I don't have the time or inclination to read it. Wake me up when it's over.
This showed up in my Schwab newsfeed about an hour ago.
Dow Jones - July 1, 2024 2:35 pm
Vitro Biopharma to Offer 1 Million Shares in Initial Public Offering
The regenerative medicine and cellular therapy company expects to price its offering between $5 a share and $6 a share, according to a securities filing. It expects net proceeds around $4.7 million based on a public offering priced at the midpoint of its guidance. Vitro intends to use the net proceeds to advance the continued development of its AlloRx Stem Cell therapy candidate, among other efforts. Vitro said its common stock has been approved for listing on the New York Stock Exchange American under the ticker VTRO.
Write to Denny Jacob at denny.jacob@wsj.com
Can’t we all get together and file a lawsuit?
OK! Mine, also with Schwab, is showing 0 as well. Derek, you still here?
@pcarew... Thanks for the info. Still at $0 in my Schwab account. There was an SEC filing this week that does suggest to me that something is happening. But I will believe it when I see it.
My vitro Biopharma stock has reappeared in my Fidelity acct with a cost basis of $17ish.
Maybe something is moving
Thanks for the laugh, I needed that! So they are still doing business, selling things and the like? Kinda surprising. Either way, looks like us shareholders are going to continue to be frozen out.
The quarterly report is out. It says the usual pile of nothingness wrapped in the the standard gobbledygook of warrants and convertible this or that. They still claim to be planning to start two clinical trials, but they have been saying this for a number of years now, so it doesn't mean anything. The only "news" of note is the sales of AlloRx for offshore treatments is picking up significantly, as demand for stem cell therapy picks up. If you missed it, an NFL quarterback (Kirk Cousins) was treated recently with AlloRx. So, who knows , maybe that business will grow and keep them afloat. "For whom and for what" is separate question, as the company seems on a 100-year path to nowhere, as though stockholders have the lifespans of biblical patriarchs.
Tom, I know, I think it's been 3.5 years since the delisting. At one point during that time, things seemed to be on the up and up and we even had reason for some optimism. Something must have fallen through. Maybe with a financing arrangement, and/or a trial didn't pan out. Who knows? A real head scratcher. Beside anything else though, I'm just so disappointed that they have never even attempted to communicate with us shareholders. A total disregard.
@grandslam... There's nothing to talk about. Speculating about a company that says nothing to its shareholders and seems to do nothing but execute quarterly financing agreements to stay afloat is exhausting and, ultimately, pointless. I've never seen anything like this. Complete silence from a CEO??? The guy has never said a word, never addressed the shareholders. The clinical trials??? What clinical trials? They never started, as far as anyone knows. What does this company even do? Is it a front for something? Some sort of weird tax write-off? Why are they bothering to pay people? Is there any plan? Any strategy? Nobody knows. And I'm tried of thinking about it. It would be nice to recover my investment someday, but at this point I don't see how that could be possible. As I've said recently, this company should rename itself Seinfeld, Inc. -- because, as far as anyone can tell, it's about nothing. It's certainly not about shareholder value, which remains at... let me check... right... zero.
Hello? Anyone there - there - there - there? I wonder if this might be the final post on this board lol.
Aaaannnd... It's May. The crickets are getting very monotonous.
NASDAQ would be nice, but how about just going back to being a penny stock? An uplisting can come later, on the heels of news.
It seems like Furman's vision was to spin off the offshore stuff to Zamora and kill the nutraceutical boondoggle, focusing on becoming a legit biotech with real clinical trials (of course, we'll never know, since Furman might as well be a projection on a wall). Unfortunately, it appears that all he has done is create an unsustainable burn rate that funds accountants, with zero progress toward the only thing that matters in this strategy -- namely, doing the clinical trials. They seem to have no interest at all in explaining to shareholders what the hold-up on those is. Nor will they admit that they literally have zero chance of a valuation that would support a listing on a major exchange until they at least start them, rendering moot all the talk about creative ways to kickstart a NASDAQ listing. It's like 2+2 is supposed to equal 5 or something, and the world is supposed to accept that. None of this makes any sense. They've had a candidate cell therapy ready for testing for something like five years. It just doesn't add up.
I've certainly curbed my enthusiasm. I wonder if they are even operating anymore. They did supposedly get $3M but did that ever materialize? Something tells me they're not a going concern anymore.
Aaaannnnd... February is now April. Crickets. They should rename this company "Seinfeld Biopharma" -- a company about nothing.
Just an utter disregard for us shareholders. Gotta say, it was a fun company to own back in the day. Remember when they announced a breakthrough in treating Covid. The delisting followed soon after.
Yes... LOL. A couple months ago it seemed evident that former insiders & investors were exerting some pressure to resume trading. But nothing ever seems to happen, other than occasional SEC filings that state some objective -- which then falls into the black hole that is their communications. Continued deafening silence from the CEO, and no updates on the only thing that really matters, which is if and when the clinical trials will ever start. So who knows. Are they just going to burn through another $3 million in darkness and silence, announcing nothing and filing required SEC documents? March will turn into April, which will become May and then June. And we'll be sitting in front of our computers asking the same questions. I suppose if those insiders and investors decide to blow it all up with lawyers, that could make a difference (though it would be the end of the road for most of us). It's not clear that the company has any intention to do anything real, unless forced to do so. They might not like to read that, but what do they expect when they don't communicate, outside of required boilerplate filings?
A minute change with my Schwab view. Instead of seeing "N/A" in one or more columns, I'm now seeing $0.00. Now that's progress lol
Yeah, it is crazy. You know, sometimes you just have to believe your lyin' eyes. When they announced the IPO at $17 million, I set up a spreadsheet with different scenarios, and tried mightily to figure out how they could make it work, considering listing requirements of a major exchange and the equity positions of Musick and Zamora. Ultimately, I just didn't see how the major investors needed for an IPO could stomach it, unless those two somehow sold into the IPO to reduce their control (which ultimately would have severely diluted legacy investors like us). But that was never going to happen. I think it might have worked if it was just Musick owing a plurality, as he is a scientist and this is his life's work. But the Zamora thing was clearly too much for rational investors to bear. I have no idea how the company allowed that to happen. All we really know is that the Furman regime took action, and subsequently stripped Zamora of direct control over his shares. I suspect they realized that they were never going to be taken seriously if they didn't do something. It's still not ideal. But anyway, yeah, one would hope the $3 million is enough for them to generate some results and establish some credibility.
Crazy shit but what else is new? Thanks for your take, as always. A good thing is that the $3M they (apparently) got fairly recently has been keeping this a going concern, with the trials etc. they've detailed in the 10-K proceeding apace. At least by all appearances, that is.
@grandslam... It can be very confusing, and I don't have the time to detangle it all. It is important to distinguish "what we care about" -- by which I mean "total number of existing shares + total number of potential shares via options, notes and warrants" -- from the share counts discussed early in the latest filing. The latter is dealing specifically with shares that will be eligible for public trading if/when they go live on the NASDAQ. I'm not particularly concerned with that. Roughly speaking, I think what they are getting at is that most/all of the Musick and Zamora shares are not part of this, but a number of shares are being created via options, notes and warrants.
But, again, I'm not really concerned about, say, the daughter of a former CFO suddenly being able to trade 3,000 shares. I'm concerned about the total share count today and the total share count that will exist if all those options and warrants become shares. The share count is 4,430,535. As best I can tell without going crazy there are 1,681,077 additional shares that could be created. That number could be (probably is) wrong in certain respects, but I think it's a decent general gauge, insofar as 1.1 million of the 1.6 million are just stock options.
Bottom line: I think there are roughly 6,000,000 shares (4.4 million + 1.6 million) either in existence now or that will likely exist if the company survives. Of these, roughly 2 million will be tradeable on the NASDAQ, if and when the listing ever happens. Which reflects the fact that Musick and Zamore own two thirds of the company (which I think, more than anything, is why the IPO likely failed).
So with the new ticker, there will be fewer shares. So there must be a formula somewhere for converting VODG shares to VTRO? I take it then that that would be the share count that's already showing on Schwab for CUSIP 928501402. How did they arrive at that share count? OK I'll have to go back and see how many I used to own.
@grandslam... If I'm reading it correctly, there will be roughly another million shares added to the total from exercise of warrants, or shares issuable under prior agreements. Of the 2,179,344 shares in the filing, 1,224,183 shares already exist, leaving 955,161 in the "to be created" category. But it is very difficult to figure all that out in a 10 minute read, particularly in light of information later in the document where they delineate all of the various outstanding warrants and their respective exercise prices. I don't have the time -- or, frankly, the interest or expertise -- to figure all that out. All that really matters is that a return to trading is looking very likely in the next few months, if the NASDAQ approves their plan and a market develops. As I've said, I think the fate of the share price will then depend heavily on their moving forward with the clinical trials this year, as advertised. If bona fide trials are underway, there should be enough speculative interest to maintain a market for the shares for a while.
With 4,430,535 shares outstanding, $15 per would make it a $66M company. Ambitious indeed. Just start trading already and let the market determine what's worth what.
They files another S-1 with the SEC that seems to formalize their previously announced plans to enter the NASDAQ without an IPO, with pricing determined by the market -- all seemingly in response to a demand for liquidity by various influential shareholders. The only real "news" here, based a quick skim, is they are setting the baseline share price at $15, until trading commences and the market speaks. At $15/share, most investors from the penny stock days would likely see a gain of 200% - 500%, depending on when you bought. Which would be nice, if it held up. But I don't expect that to hold up initially, as I don't know where the demand will be coming from, given their apparent determination to remain utterly unknown in the marketplace. But you never know. They keep doubling down on the clinical trials starting this year. Should positive early results, or rumors of same, emerge, that could provide a tailwind later this year. But I will believe all of this when I see it.
Sure, let it be a penny stock. We can always uplist later if things start to go well. Right now I'd be thrilled to see it priced at anything, a fraction of a penny or whatever. The PRs can always start then, at which point anyone can buy or sell as they wish. Ah those were the days!
@grandslam... It's discussed in some detail under "Risks Related to Ownership of our Common Stock", and also in a prior 8K. The more I think about it, the more I think it's a bad idea to relist on a major exchange, until and unless they generate some buzz with the clinical trials. If there is no demand for the stock, the price will plummet, even with the tiny float. There must be buyers. And if the price plummets, another delisting will occur, helping no one. If they are only doing this to appease shareholders who want some liquidity, but refuse to do the things necessary to create awareness of their business, it seems to me that a lower key listing on an OTC board would be more appropriate.
Tom, thanks. I attempted to go through the 10K.... lots about the business, which is good, but don't see anything about getting relisted. What section are you looking at?
The 10K (Annual Report) is out. If nothing else, they are at least filing robust reports nowadays. No, we never get to talk to the CEO to ask questions, but at least the info exists. My takeaway from skimming it is that they are serious about re-entering the equity markets, they are ready to initiate the first two clinical trials, and they plan to build a second manufacturing facility. I don't think they have the funding to do that last one this year. It seems to me that they probably have the cash to do the clinical trials or the new facility, but not both. But who knows.
So, yeah, I think this is finally the year that the logjam breaks, on multiple fronts. That doesn't mean the results will be good. It could be the year that the equity officially becomes worthless. Or, who knows, the shares could be trading at $30 this fall with some favorable buzz. But I do think we'll finally be out of the black hole we entered in 2020.
@grandslam... it's in the SEC filing.
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2891
|
Created
|
12/12/06
|
Type
|
Free
|
Moderators |
JAMES R. MUSICK
Chairman, President & CEO
Vitro Diagnostics, Inc.4621 Technology DriveGolden, CO 80403
(303) 999-2130
(303) 762-1240 – FAX
www.vitrobiopharma.com
SIC Number: 2836
Fiscal Year End: 10-31
Transfer Agent: Securities Transfer Corporation
2591 Dallas Pkwy Ste 102
Frisco, TX 75034
469-633-0101
CIK: 793171
Outstanding Shares: 17,214,000 Public Float: 11.577M
Authorized: 55M
All Share data is up to date Taken from the 10K & 10Q 2008:
In the last 12 years the OS has only been raised 8M shares
The company has been fully reporting since 1996
There has never been a Reverse Split
Nevada Secretary of State:
Copy link into your browser for Authorized Share Info
https://esos.state.nv.us/SOSServices/AnonymousAccess/CorpSearch/CorpDetails.aspx?lx8nvq=je%252b030vYJV4m6q8vvRTC9Q%253d%253d
DISCLAIMER: Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) most likely will have positions in the stock, and may/will trade a portion or all of the position in the stock mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information
http://ih.advfn.com/p.php?pid=squote&symbol=VODG
Patent Info:
Vitro's cell immortalization patent allowed.
http://www.vitrodiag.com/6_12_02.html
Press Release: Vitro granted additional fertility drug patents.
http://www.vitrodiag.com/7_23_02.html
PAT. NO. 6,414,123
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPT
PAT. NO 5,990,288
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPT....
Vitro Awarded Cell Immortalization Patent By United States Patent Office
http://www.vitrodiag.com/10_01_02.html
PAT. NO 6,458,593
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPT....
Recent patent Application that the company expects to gain a Notice of Allowance with an issued patent to follow
http://www.vitrodiag.com/US20060093586_1.pdf
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
June 23,2008 Wall Street Transcript interview...
http://www.twst.com/ceos.htm
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2007 Interview with The Wall Street Transcript
http://www.vitrodiag.com/TWST_Interview.pdf
Business Summary:
Vitro Diagnostics, Inc. dba, Vitro BioPharma (OTC Bulletin Board; VODG) is a publicly traded biotechnology firm committed to “Harnessing the Power of Cells”. The Company has generated over 30 adult human stem cell lines that drive numerous commercial opportunities in medical research and treatment of disease. Our business plan focuses on initiatives to: 1) commercialize products for use in drug development & discovery, 2) develop and commercialize products to treat animal diabetes and 3) develop and commercialize a stem cell-based treatment of human diabetes. Our advanced stem cell technology has broad application to several high-value medical products. We intend to leverage our platform technology to build a Company based on high-margin products targeting a variety of diverse markets in medical research and treatment of previously untreatable or under-treated diseases.
Executive Summary:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23705800
Informative Links regarding Pancreatic Islet Therapy:
http://www.fda.gov/cber/genetherapy/pancislet.htm
Shortage of Islets: major obstacle to widespread use of islet transplantation is the shortage of islets.
http://diabetes.niddk.nih.gov/dm/pubs/pancreaticislet/
Nearly 600 diabetes patients worldwide have now received islet transplants, and enough patients have been transplanted that long-term benefits can be documented.
http://www.jdrf.org/index.cfm?page_id=106304
Cell Therapies For Diabetes, Cancer May Be Coming Soon
http://www.medicalnewstoday.com/articles/101239.php
Pancreatic Stem Cell Transplantation
http://www.minervamedica.it/pdf/R41Y2004/R41Y2004N01A0025.pdf
Researchers are a step closer to a cure for type 1 diabetes after the successful transplantation of insulin-producing cells into eight patients.
Cell transplant dramatically changes diabetic's life
Published: Wednesday, 19-Mar-2008
http://www.news-medical.net/?id=36476
Six centres are receiving nearly £10m of government funding ( London) to offer transplants of insulin-producing cells.
http://www.worldhealth.net/p/cure-hope-over-diabetes-therapy.html
Transplants of own stem cells may let diabetics forgo insulin
http://www.baltimoresun.com/news/health/bal-te.diabetes11apr11,0,7517225.story?coll=bal-health-headlines
In Vivo Imaging of Immune Rejection in Transplanted Pancreatic Islets
http://diabetes.diabetesjournals.org/cgi/content/full/55/9/2419
SEC EDGAR Filings: Fully reporting for 12 years OS grew by only 8m shares since that time
http://knobias.10kwizard.com/files.php
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |